Daniel Bertholet
Senior Investment Director

Daniel Bertholet is an Senior Investment Director in the Life Sciences practice at Endeavour Vision, with a focus on medtech investments. Daniel has invested in ReShape Medical, Sophia Genetics, PneumRx (sold to BTG), Symetis (sold to Boston Scientific), CeQur, Nfocus (sold to Covidien), Endoart (sold to Allergan), Thommen Medical (exited), Neocutis (sold to Merz Pharma), Novalar Pharmaceuticals (exited), Molecular Partners (IPO) and Kuros (merged with Cytos), Biosurgery. He also participated in investments and/or follow-on investments in Native Networks (sold to Alcatel), eProject/Daptiv (exited), Paion (IPO), Nexx Systems (sold to Tokyo Electron) and Novimmune.

Prior to his venture capital career, Daniel was the co-founder and CFO of a technology start-up and has invested as a business angel/private investor in private companies for over 20 years in Europe and the US. Daniel started his career as a consultant in country risk assessment for Business Environment Risk Intelligence (BERI) in the US and Switzerland.

Daniel is a member of the Medtech Task Force of the European Venture Capital Association (EVCA) and has spoken at numerous industry events in the US and Europe.

Daniel holds an MBA with honours from the Institut d’Etudes Politiques in Paris and a MA in International Political Economy from the American University in Washington DC.

Daniel is personally committed to support vulnerable children in Sub-Saharan Africa. He lives in Geneva with his wife and their three children.

Daniel Bertholet

 
 
 
tel.: +41 22 544 6030
email.:
vcard: open vcard

His favourite question to entrepreneurs: « What makes you passionate about your business? »

© Endeavour Vision SA 2006-2017 Terms & Conditions